DiaMedica Therapeutics Inc. (DMAC)
NASDAQ: DMAC · Real-Time Price · USD
6.65
-0.10 (-1.48%)
At close: Aug 10, 2026, 4:00 PM EDT
6.73
+0.08 (1.27%)
After-hours: Aug 10, 2026, 7:34 PM EDT
DiaMedica Therapeutics Revenue
Revenue (ttm)
n/a
Revenue Growth
n/a
P/S Ratio
n/a
Revenue / Employee
n/a
Employees
35
Market Cap
358.32M
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | - | - | - |
| Dec 31, 2024 | - | - | - |
| Dec 31, 2023 | - | - | - |
| Dec 31, 2022 | - | - | - |
| Dec 31, 2021 | - | - | - |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Century Therapeutics | 109.16M |
| Clinuvel Pharmaceuticals | 64.24M |
| Fennec Pharmaceuticals | 51.00M |
| Foghorn Therapeutics | 36.74M |
| Compass Therapeutics | 850.00K |
| Vicore Pharma Holding AB | 370.61K |
| SAB Biotherapeutics | 114.70K |
| Lyell Immunopharma | 27.00K |
DMAC News
- Just now - DiaMedica Therapeutics Earnings release: Q2 2026 - Filings
- Just now - DiaMedica Therapeutics Quarterly report: Q2 2026 - Filings
- 6 hours ago - DiaMedica Therapeutics reports Q2 EPS (19c), consensus (20c) - TheFly
- 6 hours ago - DiaMedica Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Highlights - Business Wire
- 6 days ago - DiaMedica Therapeutics to Report Second Quarter 2026 Financial Results and Provide a Business Update August 11, 2026 - Business Wire
- 24 days ago - DiaMedica Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Business Wire
- 6 weeks ago - DiaMedica Therapeutics announces dosing of first two patients in DM199 study - TheFly
- 6 weeks ago - DiaMedica Therapeutics Announces First Patients Dosed in Phase 2 Trial of DM199 for the Treatment of Fetal Growth Restriction - Business Wire